LUCD Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Lucid Diagnostics Inc. (LUCD) is not a strong buy at the moment for a beginner investor with a long-term focus. While the company has shown revenue growth and secured important contracts, its financial performance indicates ongoing profitability challenges, and technical indicators suggest the stock is oversold but lacks clear upward momentum. Given the absence of strong trading signals and the potential for short-term volatility, holding off on investment is advisable until more favorable conditions emerge.
The stock is currently oversold with an RSI of 11.892, indicating potential for a rebound. However, the MACD histogram is negative and expanding downward, suggesting bearish momentum. The price is near its S2 support level of 1.114, with resistance at 1.287. Moving averages are converging, showing no clear trend.
Revenue growth of 25.65% YoY in Q4
Secured a contract with the U.S. Department of Veterans Affairs for EsoGuard.
Increased cash reserves to $34.7 million as of December 31,
Strong market demand for EsoGuard, with test volumes exceeding targets.
Q4 non-GAAP EPS of -$0.10 missed expectations by $0.
Gross margin dropped significantly by 65.19% YoY.
Ongoing profitability challenges with a net income of -$16.27 million in Q4
Market reacted cautiously to earnings miss, indicating potential short-term volatility.
In Q4 2025, revenue increased by 25.65% YoY to $1.5 million, and net income improved by 40.94% YoY but remained negative at -$16.27 million. EPS dropped by 40% YoY to -$0.12, and gross margin decreased significantly to -30.65%. Cash reserves increased to $34.7 million, reflecting improved liquidity.
No recent analyst rating or price target changes available.
